Professional
Added to YB: 2025-10-22
Pitch date: 2025-10-20
FNCH [neutral]
Finch Therapeutics Group, Inc.
+11.84%
current return
Author Info
No bio for this author
Company Info
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Market Cap
$19.4M
Pitch Price
$12.50
Price Target
25.00 (+79%)
Dividend
N/A
EV/EBITDA
-1.77
P/E
-1.37
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Arquitos Capital Management Portfolio Holding: Finch Therapeutics Group, Inc.
FNCH (holding update): Won jury trial vs Ferring in Aug 2024, awarded ~$30M licensing fee + ongoing royalties + post-trial interest. Jury found willful infringement, enabling 3x enhanced damages. Even worst-case scenario (no enhanced damages) values shares at 2x current price. Awaiting final judgment.
Read full article (1 min)